Business
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has executed an agreement with Østfold Hospital Trust of Norway. “It was gratifying to be selected as the supplier to Østfold Hospital Trust following a lengthy diligence and negotiation pr
About this update from Pharmala Biotech Holdings, Inc.
[{"type":"image","alt":"PharmAla Biotech","displaySize":"","headline":null,"caption":"PharmAla Biotech","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":167,"url":"https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rh7A3yGxrk9MQDPQWu1yYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866","width":300,"height":167}},"lazy":false},{"type":"text","content":"TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has executed an agreement with Østfold Hospital Trust of Norway.","length":375,"tagName":"p"},{"type":"text","content":"“It was gratifying to be selected as the supplier to Østfold Hospital Trust following a lengthy diligence and negotiation process completed over the summer and fall of 2025. We continue to be incredibly impressed with the team’s success in both executing and publishing exceptional research into MDMA as a potential treatment for Major Depressive Disorder,” said Nicholas Kadysh, CEO, PharmAla Biotech. “We are excited and committed to help support them in their goal, and look forward to delivering investigational LaNeo MDMA to them to help support this exceptional work – and gratified that our previous establishment of a value chain across Europe will be helpful in the technical operations needed to make this delivery.”","length":726,"tagName":"p"},{"type":"text","content":"The sales agreement contains both financial and data-sharing provisions. PharmAla will seek to ship its LaNeo MDMA Clinical Research Materials to Østfold Hospital Trust at the earliest opportunity, subject to customary regulatory approvals.","length":240,"tagName":"p"},{"type":"text","content":"“PharmAla was selected after a competitive review of potential manufacturers”, said Tor-Morten Kvam at Østfold Hospital Trust. “Their demonstrated professionalism and understanding of the regulatory and scientific requirements for clinical research made them a strong partner for this study.”","length":292,"tagName":"p"},{"type":"text",...